Research map: DNA polymerase theta (Polθ): a novel candidate for targeted cancer therapy

Back to the article

Papers in this map

  1. Hallmarks of Cancer: The Next Generation · Douglas Hanahan · 2011 · 67934 citations · Cited by this paper
  2. Validation of the important role and prognostic value of KIF14 in triple-negative breast cancer · 2025 · Related
  3. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries · Freddie Bray · 2024 · 26051 citations · Cited by this paper
  4. NCAPD2 promotes the progression of lung adenocarcinoma through an AKT/MDM2/E2F1 positive feedback loop · 2025 · Related
  5. Hallmarks of Cancer: New Dimensions · Douglas Hanahan · 2022 · 9836 citations · Cited by this paper
  6. Parthenolide inhibits the progression of intrahepatic cholangiocarcinoma by promoting ferroptosis through inhibiting UBD · 2026 · Related
  7. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase · Helen E. Bryant · 2005 · 5275 citations · Cited by this paper
  8. Assessing progesterone receptor modulation in glioblastoma: from in vitro and animal model to a human pilot protocol · 2025 · Related
  9. PARP inhibitors: Synthetic lethality in the clinic · Christopher J. Lord · 2017 · 2989 citations · Cited by this paper
  10. Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma · 2026 · Related
  11. Targeting DNA damage response pathways in cancer · Florian J. Groelly · 2022 · 874 citations · Cited by this paper
  12. The dual role of leukotrienes in the tumor microenvironment: balancing pro-tumorigenic and anti-tumor immunity · 2026 · Related
  13. Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination · Pedro A. Mateos‐Gómez · 2015 · 791 citations · Cited by this paper
  14. Downregulation of the lncRNA PGM5P4-AS1 predicts poor prognosis and drives breast cancer progression through miR-3664-5p/KLF9 · 2025 · Related
  15. Synthetic lethality and cancer · Nigel J. O’Neil · 2017 · 708 citations · Cited by this paper
  16. Jujuboside A induces bladder cancer cell apoptosis by inhibiting ATP1A2-mediated mitochondrial energy metabolism regulation · 2026 · Related
  17. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study · Saro H. Armenian · 2016 · 567 citations · Cited by this paper
  18. Toll-like receptor 4 inhibition sensitizes non-small cell lung cancer to radiotherapy · 2025 · Related
  19. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases · Helen Strongman · 2019 · 524 citations · Cited by this paper
  20. A patent review of DNA polymerase theta (Polθ) targeted therapies (2019–2025) · 2026 · Related
  21. Synthetic lethality as an engine for cancer drug target discovery · Alan Huang · 2019 · 488 citations · Cited by this paper
  22. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors? · Alan Ashworth · 2018 · 434 citations · Cited by this paper
  23. Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase θ · Tatiana Kent · 2015 · 345 citations · Cited by this paper
  24. Cardiovascular disease and cancer: shared risk factors and mechanisms · Nicholas S. Wilcox · 2024 · 304 citations · Cited by this paper
  25. DNA polymerase θ up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability · Fanny Lemée · 2010 · 229 citations · Cited by this paper
  26. FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair · Zeina Kais · 2016 · 214 citations · Cited by this paper
  27. Synthetic Lethality in Cancer Therapeutics: The Next Generation · Jeremy S. Setton · 2021 · 210 citations · Cited by this paper
  28. The helicase domain of Polθ counteracts RPA to promote alt-NHEJ · Pedro A. Mateos‐Gómez · 2017 · 205 citations · Cited by this paper
  29. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy · Charlie Gourley · 2019 · 202 citations · Cited by this paper
  30. DNA repair defects in cancer and therapeutic opportunities · Jessica L. Hopkins · 2022 · 202 citations · Cited by this paper
  31. Targeted protein degradation for cancer therapy · Matthias Hinterndorfer · 2025 · 196 citations · Cited by this paper
  32. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy · Chao Wang · 2024 · 185 citations · Cited by this paper
  33. Genetic determinants of cellular addiction to DNA polymerase theta · Wanjuan Feng · 2019 · 181 citations · Cited by this paper
  34. Mechanistic basis for microhomology identification and genome scarring by polymerase theta · Juan Carvajal-Garcia · 2020 · 173 citations · Cited by this paper
  35. Mutational signatures of non‐homologous and polymerase theta‐mediated end‐joining in embryonic stem cells · Joost Schimmel · 2017 · 158 citations · Cited by this paper
  36. DNA polymerase θ is preferentially expressed in lymphoid tissues and upregulated in human cancers · Kiyoko Kawamura · 2003 · 144 citations · Cited by this paper
  37. Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis · Orly Leiva · 2021 · 144 citations · Cited by this paper
  38. RHINO directs MMEJ to repair DNA breaks in mitosis · Alessandra Brambati · 2023 · 142 citations · Cited by this paper
  39. A new wave of innovations within the DNA damage response · Qi Li · 2023 · 142 citations · Cited by this paper

Source: OpenAlex (CC0)